By identifying epithelial pathways that remain vulnerable even in the presence of IL-13 blockade, this study identifies new potential therapeutic targets for children with T2-high asthma who continue to experience viral-triggered exacerbations despite biologic therapy. Here, IL13 is linked to asthma.